Candel Therapeutics Announces Pricing of Initial Public Offering NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...

Candel Therapeutics Completes $28.7 Million Series B Financing Proceeds to Accelerate Enrollment of Phase 3 Localized Prostate Cancer Clinical Trial and to Advance Late Stage High-Grade Glioma Clinical Program Candel to Expand Clinical Trials in Other...

Advantagene Announces Clinical Trial Collaboration AUBURNDALE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Advantagene, Inc. today announced that the company entered into a clinical trial collaboration with Bristol-Myers Squibb (NYSE:BMY) to evaluate...